ULC1452T_S57
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.500
- OXIDATIVE_PHOSPHORYLATION+0.480
- FATTY_ACID_METABOLISM+0.400
- ADIPOGENESIS+0.380
- CHOLESTEROL_HOMEOSTASIS+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.340
- ESTROGEN_RESPONSE_LATE+0.300
- DNA_REPAIR+0.290
- ANDROGEN_RESPONSE+0.280
- G2M_CHECKPOINT+0.260
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- ALLOGRAFT_REJECTION-0.400
- IL6_JAK_STAT3_SIGNALING-0.390
- INFLAMMATORY_RESPONSE-0.290
- HEDGEHOG_SIGNALING-0.250
- INTERFERON_GAMMA_RESPONSE-0.240
- ANGIOGENESIS-0.220
- SPERMATOGENESIS-0.220
- KRAS_SIGNALING_UP-0.200
- APICAL_SURFACE-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CF-A3MG-01A-11R-A20F-07 | — | — | 0.843 |
| 2 | SRR1516051 | — | — | 0.835 |
| 3 | SRR1516054 | — | — | 0.815 |
| 4 | TCGA-78-7220-01A-11R-2039-07 | — | cohortA4 | 0.812 |
| 5 | R408 | — | — | 0.808 |
| 6 | TCGA-IQ-7632-01A-11R-2081-07 | — | — | 0.805 |
| 7 | E3887082-4C43-426C-8580-ECAA4EFEC577 | — | — | 0.804 |
| 8 | MNG434 | — | — | 0.798 |
| 9 | ULC0410T_S45 | — | cohortA4 | 0.796 |
| 10 | ee24b470-4509-4687-a91e-6d2b967336b9 | — | — | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.380 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.360 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.230 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |